Showing: 1 - 4 of 4 RESULTS

Happify Health Launches “2020 Survival Kit” in Support of World Mental Health Day

The new collection includes free content to help people manage stress around the election, racial injustice and discrimination, and the pandemic

In support of World Mental Health Day on October 10th, leading digital mental health company, Happify Health, today announced the launch of the “2020 Survival Kit” available today at 2020.happify.com. This new collection offers free, tailored content designed to help people manage the stressful and challenging times being faced right now amid the upcoming U.S. Presidential election, racial inequities and discrimination, and overall stress and uncertainty around the pandemic. World Mental Health Day aims to raise awareness of mental health issues around the world and mobilize efforts in support of mental health.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201009005080/en/

Happify Health has released a “2020 Survival Kit” in support of World Mental Health Day featuring free content designed to help people with the specific challenges they may be going through right now, with tracks to help manage increased stress and worry around the upcoming U.S. Presidential election, racial discrimination and injustice, and the COVID-19 pandemic. (Graphic: Business Wire)

The 2020 Survival Kit features content developed to help people cope with the additional challenges they may be experiencing right now, and includes the following tracks:

  • Find More Peace in Election Season: Manage the negative effects of the stress and anxiety you’re feeling about the state of the country and the world, and nurture your own well-being through self-care, safe social connection, and meditation.

  • Cope with Racial Stress and Discrimination: From racial discrimination to health disparities, the mental toll on the Black community is enormous. This track provides strategies to reduce negative feelings, and promote pride, meaning, and joy.

  • Managing Stress in Uncertain Times: Uncertainty goes hand in hand with intense stress and anxiety. This track helps you cope with worry while finding meaning and moments of joy during COVID-19.

  • Conquer Negative Thoughts: When things are hard, negative thinking has a tendency to grab us and not let go. This track helps you fight back against those thoughts while building resilience.

  • Your Anxiety Antidote: Mindfulness Meditation: A mindfulness practice focused on reducing anxiety can help you cope with a chaotic world and recharge your resilience.

“Now more than ever, access to digital mental health tools like Happify is critical to helping people manage the rapidly increasing stress and worry they’re experiencing – whether resulting from the pandemic, the upcoming election, racial discrimination or a combination of it all,” said Tomer Ben-Kiki, Co-Founder and CEO at Happify Health. “In support of World Mental Health Day, we are especially committed to delivering accessible mental health resources, such as our free 2020 Survival Kit, to help people cope with specific challenges they may be experiencing during this difficult year.”

Mental health disorders have been compounded by stress around the upcoming U.S. Presidential election, racial injustice and COVID-19, scaling the problem into a global crisis, and increasing the demand for digital mental health tools that will deliver people the

Immunotherapy drug boosts survival for lung cancer patients

A newly approved drug for the leading form of the number one cancer killer, lung cancer, does improve patient survival, a new study confirms.

The immunotherapy drug Tecentriq, or atezolizumab, was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diagnosed non-small cell lung cancers, or NSCLC, which comprise up to 85% of all lung tumors.

Tecentriq targets a protein known as PD-L1 that lies on the surface of tumor cells. Normally, this protein signals the body’s immune system T cells not to attack. However, by targeting PD-L1, Tecentriq unleashes the body’s natural T cells to target and destroy these cancer cells, researchers at Yale Cancer Center explained.

Tecentriq “has already shown excellent activity in patients who progress on frontline chemotherapy, but this study confirmed that the drug is active in selected patients who have not yet received any treatment for lung cancer,” said medical oncologist Dr. Nagashree Seetharamu, who treats lung cancer patients but wasn’t involved in the new study. She practices at Northwell Health Cancer Institute in Lake Success, N.Y.

The new study was funded by Tecentriq’s maker, Genentech, and the results were published this week in the New England Journal of Medicine.

The study included 554 patients with stage 4 metastatic NSCLC tumors. All patients had tumors lacking mutations in the EGFR or ALK genes: As the researchers explained in a Yale news release, tumors with those mutations are better treated with other drugs.

Among 205 patients whose tumors had high cellular expression of PD-L1, the median overall survival was 20 months for those who received Tecentriq versus 13 months for those who received standard platinum-based chemotherapy.

Median progression-free survival — the time from treatment to the disease beginning to worsen — was eight months for patients who received Tecentriq versus five months for those on standard chemotherapy, the researchers found.

“These are exciting results that could be life-changing for many patients,” said study lead author Dr. Roy Herbst. He is chief of medical oncology at the Yale Cancer Center as well as the Smilow Cancer Hospital.

“Lung cancer is the most common cancer worldwide, with more than 1.5 million patients diagnosed each year. Half of patients are diagnosed with metastatic disease, and they could be a candidate for this drug,” Herbst said in the news release.

“Also encouraging is that [Tecentriq] was generally well tolerated,” said Herbst, who is also associate cancer center director for translational research at the Yale Cancer Center in New Haven, Conn. “Side effects for patients were similar to those seen in other trials of the drug, which has been approved for treatments of several types of cancer.”

The trial also assessed how Tecentriq performed among patients with a “high tumor mutational burden,” which means that they had high levels of genetic mutations in scraps of cancer DNA detected in blood tests. In some types of cancers, high mutational burden is tied to better responses to immunotherapy drugs like Tecentriq.

“Among these patients with NSCLC,

Immunotherapy Drug Boosts Survival for Lung Cancer Patients | Health News

By Robert Preidt, HealthDay Reporter

(HealthDay)

THURSDAY, Oct. 1, 2020 (HealthDay News) — A newly approved drug for the leading form of the number one cancer killer, lung cancer, does improve patient survival, a new study confirms.

The immunotherapy drug Tecentriq (atezolizumab) was approved earlier this year by the U.S. Food and Drug Administration to treat patients with newly diagnosed non-small cell lung cancers (NSCLC), which comprise up to 85% of all lung tumors.

Tecentriq targets a protein known as PD-L1 that lies on the surface of tumor cells. Normally, this protein signals the body’s immune system T cells not to attack. However, by targeting PD-L1, Tecentriq unleashes the body’s natural T cells to target and destroy these cancer cells, researchers at Yale Cancer Center explained.

Tecentriq “has already shown excellent activity in patients who progress on frontline chemotherapy, but this study confirmed that the drug is active in selected patients who have not yet received any treatment for lung cancer,” said medical oncologist Dr. Nagashree Seetharamu, who treats lung cancer patients but wasn’t involved in the new study. She practices at Northwell Health Cancer Institute in Lake Success, N.Y.

The new study was funded by Tecentriq’s maker, Genentech, and the results were published Sept. 30 in the New England Journal of Medicine.

The study included 554 patients with stage 4 metastatic NSCLC tumors. All patients had tumors lacking mutations in the EGFR or ALK genes: As the researchers explained in a Yale news release, tumors with those mutations are better treated with other drugs.

Among 205 patients whose tumors had high cellular expression of PD-L1, the median overall survival was 20 months for those who received Tecentriq versus 13 months for those who received standard platinum-based chemotherapy.

Median progression-free survival — the time from treatment to the disease beginning to worsen — was eight months for patients who received Tecentriq versus five months for those on standard chemotherapy, the researchers found.

“These are exciting results that could be life-changing for many patients,” said study lead author Dr. Roy Herbst. He is chief of medical oncology at the Yale Cancer Center as well as the Smilow Cancer Hospital.

“Lung cancer is the most common cancer worldwide, with more than 1.5 million patients diagnosed each year. Half of patients are diagnosed with metastatic disease, and they could be a candidate for this drug,” Herbst said in the news release.

“Also encouraging is that [Tecentriq] was generally well tolerated,” said Herbst, who is also associate cancer center director for translational research at the Yale Cancer Center in New Haven, Conn. “Side effects for patients were similar to those seen in other trials of the drug, which has been approved for treatments of several types of cancer.”

The trial also assessed how Tecentriq performed among patients with a “high tumor mutational burden,” which means that they had high levels of genetic mutations in scraps of cancer DNA detected in blood tests. In some types of cancers, high mutational burden is tied to

Survival Vegetation That Can Save You

Nursing interventions for acute pain are necessary because more often than not a affected person in acute ache is not used to being in ache. The bag held treasured natural medicines or particular objects. In 2012, Dr. Estuita found that chelation therapy can also be safe and effective for the remedy of hepatitis B. He has already handled 20 hepatitis B sufferers.

Sulfonylureas group of medicines help the physique to make more or required insulin. The unwanted effects of Steroid medicines are weakening bones, thinning of skin and rising blood sugar degree. Water: As I discussed, biotin is a water-soluble vitamin, so drink lots and lots of water—well being authorities advocate two liters, or eight cups, a day usually.

These medicines block the transport of calcium into the smooth cells lining the coronary arteries and different arteries of the body. handout written materials on a medication that sufferers are taking to include uncomfortable side effects and different drug interactions.

They don’t notice that the animals they imagine are being harmed, have not solely impacted their lives ultimately, however have impacted their households, buddies, and kids by providing people with vaccines and antibiotics which are deserving of more accreditation than what they label them.

Medicine and Radiology :- It is a specialisation involved with the non-surgical medical points of is concerned with primary diagnosis and therapy of oral ailments that don’t reply to standard dental procedures.Radiology deals with the radiographs(x-rays) of teeth and their associated structures.…